

MARKERS FOR DIGESTIVE DISORDERS

Effective Date: May 1, 2025

Review Dates: 2/11, 2/12, 2/13, 2/14, 2/15, 2/16,
11/16, 8/17, 11/17, 11/18, 11/19, 11/20, 11/21, 11/22,
5/23, 5/24, 2/25

Date Of Origin: February 9, 2011

Status: Current

Summary of Changes

- Addition/Clarification:
 - I.A. 6.e: Proactive therapeutic drug monitoring (e.g., PredictrPK IFX) to predict therapeutic response is not medically necessary for the management of IBD or UC.
 - I.C: Methane and hydrogen breath tests are medically necessary for the diagnosis of lactose intolerance. Home breath tests are not medically necessary (e.g., Trio-Smart).

I. POLICY/CRITERIA**A. Inflammatory digestive disorders**

1. Measurements of serum concentration of infliximab (IFX) or adalimumab (ADA) or vedolizumab (VDZ) or ustekinumab (UST) for reactive therapeutic drug monitoring of members with active inflammatory bowel disease (IBD) treated with anti-tumor necrosis factor (TNF) agents are considered medically necessary.
2. Measurements of anti-drug antibody to infliximab or adalimumab or vedolizumab or ustekinumab are medically necessary to assess therapy response (i.e., dose escalation) when the biologic agent drug level is below the therapeutic range and limited to 1 test per 6 months. Routine or serial testing is not medically necessary due to insufficient evidence demonstrating improvement in clinical outcomes or management.
3. Thiopurine methyltransferase (TPMT) phenotype (analysis of enzyme activity) and genotype (identification of specific variants) testing for thiopurine drug response may be medically necessary according to EviCore guidelines.
4. 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine nucleotide (6-MMPN) measurements (e.g., PRO-PredictR 6MP / azathioprine, PRO-Predict Metabolites) are medically necessary to monitor compliance in those not responding to 6-MP or azathioprine and to assess suspected toxicity.
5. Fecal measurement of calprotectin is medically necessary for the management of inflammatory bowel diseases (e.g., Crohn's disease,

ulcerative colitis). It is not medically necessary for other indications because its clinical utility has not been established.

6. The following tests are experimental and investigational because their clinical utility has not been established.
 - a. Crohn's disease peptide antibody testing
 - b. ECM1 and Stat-3 testing for ulcerative colitis
 - c. Measurement of serum mannose-binding lectin
 - d. Myeloperoxidase antibody testing for inflammatory bowel disease,
 - e. Proactive therapeutic drug monitoring to predict therapeutic response in the management of IBD or UC (e.g., PredictrPK IFX)
 - f. Proteinase-3 antibody testing,
 - g. Raman spectroscopy for inflammatory bowel disease.

B. Celiac Disease

1. Serological testing of IgA anti-human tissue transglutaminase (TTG) antibodies (TGA), and IgA anti-endomysial antibodies (EMA) are medically necessary for any of the following indications:
 - a. As a preliminary diagnostic test for persons with symptoms suggestive of celiac disease; *or*
 - b. To monitor response to a gluten-free diet; *or*
 - c. To screen first-degree relatives of individuals with celiac disease; *or*
 - d. To screen persons with type 1 diabetes for celiac disease.
2. IgG-TTG and IgG-EMA are medically necessary for persons with symptoms suggestive of celiac disease and a serum IgA deficiency.
3. Deamidated gliadin antibodies (DGP) testing is medically necessary if IgA deficiency is present.
4. Serological tests individually or as part of a panel (IgA-AGA, IgG-AGA, IgA-TTG, and IgA-EMAt) for celiac disease (i.e. PROMETHEUS® Celiac PLUS, PROMETHEUS® Celiac Serology) are experimental and investigational as an alternative to biopsy for assessing mucosal damage in individuals with celiac disease, and for all other indications.
5. Genetic testing for HLA-DQ2 and HLA-DQ8 haplotypes is medically necessary ONLY for members with symptoms suggestive of celiac disease and indeterminate serology results. Genetic testing as initial screening in symptomatic or in asymptomatic individuals is experimental and investigational (i.e., MyCeliacID, PROMETHEUS® Celiac Genetics).
6. The following tests are experimental and investigational for the diagnosis of celiac disease: (not an all-inclusive list):
 - D-xylose and/or lactulose absorption test
 - Intestinal permeability tests
 - Salivary tests
 - Small-bowel follow-through (barium follow-through examination)
 - Stool studies

C. Hydrogen and Methane Breath Tests

1. Hydrogen and methane breath testing are considered medically necessary for suspected lactose intolerance.
2. At-home hydrogen and methane breath testing are not medically necessary.
 - i. Trio-Smart Breath Test is experimental and investigational.

II. MEDICAL NECESSITY REVIEW

Prior authorization for certain drug, services, and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service, or procedure is medically necessary. For more information, please refer to the [Priority Health Provider Manual](#).

All tests performed at non-participating laboratories will require prior authorization; and as indicated.

III. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- ❖ **HMO/EPO:** *This policy applies to insured HMO/EPO plans.*
- ❖ **POS:** *This policy applies to insured POS plans.*
- ❖ **PPO:** *This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.*
- ❖ **ASO:** *For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.*
- ❖ **INDIVIDUAL:** *For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.*
- ❖ **MEDICARE:** *Coverage is determined by the Centers for Medicare and Medicaid Services (CMS) and/or the Evidence of Coverage (EOC); if a coverage determination has not been adopted by CMS, this policy applies.*
- ❖ **MEDICAID/HEALTHY MICHIGAN PLAN:** *For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html, the Michigan Medicaid Provider Manual will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.*

IV. DESCRIPTION

Inflammatory bowel disease (IBD) includes two major disorders: ulcerative colitis (UC) and Crohn disease (CD). UC affects the colon and is characterized by

inflammation of the mucosal layer. CD is characterized by transmural inflammation and may involve any portion of luminal gastrointestinal tract, from the oral cavity to the perianal area.

Crohn's disease has an unknown etiology that may be influenced by genetic, immunologic, and environmental factors. The American College of Gastroenterology (AGA) Practice Guidelines for Management of Crohn's disease in adults (Lichtenstein et al., 2018) states that the diagnosis of Crohn's disease (CD) is based on a combination of clinical presentation and endoscopic, radiologic, histologic, and pathologic findings that demonstrate some degree of focal, asymmetric, and transmural granulomatous inflammation of the luminal GI tract. Laboratory testing is complementary in assessing disease severity and complications of disease. There is no single laboratory test that can make an unequivocal diagnosis of CD. The sequence of testing is dependent on presenting clinical features. Routine use of serologic markers of IBD to establish the diagnosis of Crohn's disease is not indicated.

Ulcerative colitis is a chronic immune-mediated inflammatory disease in which abnormal reactions of the immune system cause inflammation and ulcers on the inner lining of the large intestine (NIDDK, 2020). The American College of Gastroenterology Ulcerative Colitis Practice Guidelines in Adults (2019) states that serologic markers such as perinuclear antineutrophil cytoplasmic antibodies (pANCA) may be found in up to 70% of patients with UC, and combination of negative anti-Saccharomyces cerevisiae antibodies with elevated pANCA levels has been proposed to facilitate establishing a diagnosis of UC. However, the pooled sensitivity of antibody testing for diagnosis of UC is low, and such markers are not used for establishing or ruling out a diagnosis of UC. Although pANCA positivity has also been associated with treatment refractory UC, the evidence supporting this is limited, and there is currently no role for such testing to determine the likelihood of disease evolution and prognosis.

The North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America consensus conference report on differentiating UC from CD in children and young adults (Bousvaros, et al., 2007) states that the value of serology in a patient with IC remains a topic of study, and further research should examine, among other areas, the role of surrogate laboratory markers (genetics, serology, microbiology) in distinguishing these entities. A proposed algorithm to assist clinicians in differentiating UC from CD does not include serological testing.

The American Gastroenterological Association Clinical Guidelines for Therapeutic Drug Monitoring in Inflammatory Bowel Disease (Feuerstein et al, 2017) suggests reactive therapeutic drug monitoring (TDM) to guide treatment changes in adults with active IBD treated with anti-TNF agents. However, the AGA does not recommend the use of routine proactive therapeutic drug monitoring in adult patients with inactive IBD treated with anti-TNF agents.

Defined as the assessment of drug concentrations and anti-drug antibodies, TDM, is an important tool for optimizing biologic therapy. Anti-drug antibody testing in patients who are undergoing treatment for IBD has been proposed to help determine whether ongoing treatment is safe and effective and whether changes are needed. Many patients who initially benefit from treatment experience a gradual decline or loss of treatment efficacy, which is often attributable to formation of anti-drug antibody that inactivate or accelerate the clearance of the drugs from the bloodstream. Anti-drug antibody levels are usually measured with an enzyme-linked immunosorbent assay (ELISA), but in patients who are undergoing treatment with ADA, IFX, UST, VDZ, detecting ATI with a conventional ELISA is often not possible because of interference by the drugs in the blood sample. This interference can be overcome, but it requires specialized sample processing or a more complex assay technique. Prometheus Anser tests (Anser ADA, IFX, UST, and VDZ) are novel laboratory-developed tests that measure both serum drug and anti-drug antibodies. An Expert Consensus Development Meeting consisting of members of the BRIDGE group and TDM specialists reached consensus statements on the application of TDM in clinical practice (Papamichael, 2019) including when it would be appropriate to order drug/antibody concentration testing.

Celiac disease is an autoimmune disease of the small intestine caused by sensitivity to dietary gluten and related proteins that occurs in genetically predisposed people. Celiac disease has a wide spectrum of clinical manifestations that resemble a multisystemic disorder rather than an isolated intestinal disease and is characterized by small bowel injury and the presence of specific antibodies (Rubio-Tapia, 2023). In patients with celiac disease, immune responses to gliadin fractions promote an inflammatory reaction, characterized by infiltration of the lamina propria and the epithelium with chronic inflammatory cells and villous atrophy. Serologic evaluation of tissue transglutaminase (tTG)-immunoglobulin A (IgA) antibody is the preferred test for detection of celiac disease in adults. Serologic testing of serum tissue transglutaminase (tTG)-immunoglobulin A (IgA) and endomysial (EMA)-IgA antibody tests have high sensitivities. Intestinal biopsy is required in most patients to confirm the diagnosis.

According to the American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease (2023), genetic testing for CD-compatible human leukocyte antigen (HLA) haplotype is not required for diagnosis in all cases but may be helpful in selected situations such as in the context of serology-histology discrepancy. In a change from their previous guidelines, ACG no longer recommends the use of AGA antibodies to test for celiac disease (Rubio-Tapia, 2023). Assays for deamidated gliadin peptide (DGP) antibodies have been shown to have reasonably high accuracy. The use of anti-reticulon antibodies (ARA) in the diagnosis of celiac disease has fallen out of favor. While IgA antibodies to reticulon connective tissue did see some use, primarily in pediatric celiac disease evaluation, and appeared to have test performance equal to or better than AGA, ARA was largely supplanted first by

AGA for technical reasons and later on by EMA and tTG which had markedly better test performance (Adriaanse et al, 2015). In a review of literature and recommendations for serologic evaluation for celiac disease by Nandiwata and colleagues (2013), it was concluded that ARA assays lack optimal sensitivities and specificities for routine diagnostic use.

The USPSTF (2017) found inadequate evidence regarding the accuracy of screening tests for celiac disease in asymptomatic populations. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for celiac disease in asymptomatic persons. Evidence is lacking, and the balance of benefits and harms cannot be determined.

Hydrogen/Methane Breath Testing

Hydrogen and methane breath testing is a non-invasive, accurate, standard method of diagnosing lactose intolerance. [Lactose intolerance](#) has a high prevalence worldwide, ranging between 57% and 65%. It is caused by a reduction or loss of the activity of the [intestinal enzyme](#) lactase–phlorizin hydrolase, responsible for the digestion of lactose. This alteration determines an increased osmotic load in the [small intestine](#) and the fermentation of lactose by the [bacterial flora](#), which leads to a high production of short-chain fatty acids and gas. This is followed by the onset of abdominal pain, diarrhea, and [flatulence](#). The diagnosis is essential to undertake an adequate treatment and, for this purpose, different methods have been tested. These include genetic test, hydrogen [breath test](#) (HBT), quick [lactase](#) test, and [lactose tolerance test](#). HBT is the most used method because it is non-invasive, inexpensive, and highly sensitive and specific, as well as easy to perform. (Catanzaro et al., 2021). According to the American Society for Clinical Laboratory Science (ASCLS), hydrogen breath testing(H₂) is traditionally performed in an outpatient laboratory setting. A meta-analysis by Marton, Xue, and Szilagyi (2012) comparing the diagnostic accuracy of lactose H₂ breath tests found an overall sensitivity of 0.88 (CI 0.85–0.90) and specificity of 0.85 (CI 0.82–0.87). Home hydrogen breath testing has not been proven to be a reliable diagnostic method in current peer-reviewed, published literature.

Professional Society Guidelines/Position Statements

American College of Gastroenterology [Clinical Guideline: Small Intestinal Bacterial Overgrowth](#) (2020) suggest the use of breath testing (glucose hydrogen or lactulose hydrogen) for the diagnosis of SIBO in patients with IBS (conditional recommendation, very low level of evidence), glucose hydrogen or lactulose hydrogen breath testing for the diagnosis of SIBO in symptomatic patients with suspected motility disorders” (conditional recommendation, very low level of evidence) and testing for SIBO using glucose hydrogen or lactulose hydrogen breath testing in symptomatic patients (abdominal pain, gas, bloating, and/or diarrhea) with previous luminal abdominal surgery" (conditional recommendation, very low level of evidence).

[Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus](#) (2017) suggest breath testing in the diagnosis of small intestinal bacterial overgrowth (moderate quality evidence) and to evaluate for excessive methane excretion on breath test in association with clinical constipation and slowing of gastrointestinal transit” (moderate quality evidence)

V. CODING INFORMATION

ICD-10 Codes that may apply:

D50.0	Iron deficiency anemia secondary to blood loss (chronic)
D63.8	Anemia in other chronic diseases classified elsewhere
K50.00 – K50.919	Crohn's disease
K51.00 – K51.919	Ulcerative colitis
K52.2X	Allergic and dietetic gastroenteritis and colitis
K52.89	Other specified noninfective gastroenteritis and colitis
K52.9	Noninfective gastroenteritis and colitis, unspecified
K58.0 – K58.9	Irritable bowel syndrome
K59.8X	Other specified functional intestinal disorders
K59.9	Functional intestinal disorder, unspecified
K90.0	Celiac disease
K90.1	Tropical sprue
K90.41	Non-celiac gluten sensitivity
K90.49	Malabsorption due to intolerance, not elsewhere classified
K90.89	Other intestinal malabsorption
K90.9	Intestinal malabsorption, unspecified
K92.1	Melena
K92.2	Gastrointestinal hemorrhage, unspecified
P78.9	Perinatal digestive system disorder, unspecified
R11.0 – R11.2	Nausea and vomiting
R19.4	Change in bowel habit
R19.5	Other fecal abnormalities
R19.7	Diarrhea, unspecified
R19.8	Other specified symptoms and signs involving the digestive system and abdomen
R63.8	Other symptoms and signs concerning food and fluid intake
R93.5	Abnormal findings on diagnostic imaging of other abdominal regions, including retroperitoneum

CPT/HCPCS Codes:

Codes are covered or not covered based on indications in this policy:

81375	HLA Class II typing, low resolution (eg, antigen equivalents); HLA-DRB1/3/4/5 and -DQB1
81382	HLA Class II typing, high resolution (i.e., alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each

- 81383 HLA Class II typing, high resolution (ie, alleles or allele groups); 1 allele or allele group (eg, HLA-DQB1*06:02P), each
- 81335 TPMT (thiopurine S-methyltransferase) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3) **PA through eviCore. Not covered for Medicaid**
- 81479 Unlisted molecular pathology procedure (*Explanatory note must accompany claim*)
- 81596 Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver
- 82397 Chemiluminescent assay
- 82542 Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen (*Not Covered for Medicaid*)
- 82552 Creatine kinase (CK), (CPK); isoenzymes
- 82657 Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen *Not covered for Medicaid*
- 82784 Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each
- 83516 Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method
- 83519 Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (e.g., RIA)
- 83520 Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
- 83993 Calprotectin, fecal
- 84433 Thiopurine S-methyltransferase (TPMT)
- 84620 Xylose absorption test, blood and/or urine
- 84999 Unlisted chemistry procedure
- 81599 Unlisted multianalyte assay with algorithmic analysis (*Explanatory notes must accompany claims billed with unlisted codes.*)
- 86021 Antibody identification; leukocyte antibodies
- 86140 C-reactive protein
- 86255 Fluorescent noninfectious agent antibody; screen, each antibody
- 86256 Fluorescent noninfectious agent antibody; titer, each antibody
- 88344 Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure
- 88346 Immunofluorescence, per specimen; initial single antibody stain procedure
- 88350 Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
- 0034U TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15) (e.g., thiopurine metabolism), gene analysis, common variants (i.e., TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)
- 0286U CEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants

- 0430U Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative
(Not Covered)
- 0514U Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter ($\mu\text{g/mL}$)
- 0515U Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter ($\mu\text{g/mL}$)

Breath Tests**ICD-10 Codes**

Diagnosis codes not covered:

- A04.9 - Bacterial intestinal infection, unspecified
K52.9 - Noninfective gastroenteritis and colitis, unspecified
K59.04 - Chronic idiopathic constipation
R63.4 - Abnormal weight loss
K90.9 - Intestinal malabsorption, unspecified
Z00.00 - Encounter for general adult medical examination without abnormal findings

CPT/HCPCS Codes:

- 91065 Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit)

VI. REFERENCES

1. Adriaanse M, Leffler DA. Serum markers in the clinical management of celiac disease. *Dig Dis*. 2015;33(2):236-243. Epub 2015 Apr 22. PMID: 25925929
2. Al Hadithy AF, de Boer NK, Derijks LJ, et al. Thiopurines in inflammatory bowel disease: Pharmacogenetics, therapeutic drug monitoring and clinical recommendations. *Dig Liver Dis*. 2005; 37(4):282-297.
3. Anderson RP. Coeliac disease. *Aust Fam Physician*. 2005; 34(4):239-242.
4. Bai JC et al. World Gastroenterology Organisation Global Guidelines: Celiac Disease February 2017. *J Clin Gastroenterol*. 2017 Oct;51(9):755-768. doi: 10.1097/MCG.0000000000000919. Erratum in: *J Clin Gastroenterol*. 2019 Apr;53(4):313. PMID: 28877080.
5. Bernstein CN, Eliakim A, Fedail S, et al. World Gastroenterology Organisation global guidelines inflammatory bowel disease: update August 2015. *J Clin Gastroenterol*. 2016;50(10):803-818.
6. Bhattacharya A, Travis D, Osterman MT, et al. Supratherapeutic infliximab levels do not predict risk of short-term complications in adults with crohn's disease. *J Clin Gastroenterol*. 2023;57(1):66-73.

7. Bossuyt X. Serologic markers in inflammatory bowel disease. *Clin Chem*. 2006; 52(2):171-181.
8. Bossuyt P, Pouillon L, Claeys S, D'Haens S, Hoefkens E, Strubbe B, Marichal D, Peeters H. Ultra-proactive therapeutic drug monitoring of infliximab based on point of care testing in inflammatory bowel disease: results of a pragmatic trial. *J Crohns Colitis*. 2022;16(2):199-206.
9. Bouden S, Laadhar L, Soua J, et al. No correlation between anti-drug antibodies and therapeutic response in tunisian patients with chronic inflammatory diseases treated by tnf blockers. *Curr Rheumatol Rev*. 2024;20(4):435-443.
10. Cao WT, Huang R, Jiang KF, Qiao XH, Wang JJ, Fan YH, Xu Y. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: a systematic review. *World J Gastroenterol*. 2021;27(9):886-907.
11. Catanzaro R, Sciuto M, Marotta F. Lactose intolerance: An update on its pathogenesis, diagnosis, and treatment. *Nutr Res*. 2021 May;89:23-34. doi: 10.1016/j.nutres.2021.02.003. Epub 2021 Mar 21. PMID: 33887513.
12. Chamailard M, Iacob R, Desreumaux P, Colombel JF. Advances and perspectives in the genetics of inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2006; 4(2):143-151.
13. Chanchlani N, Lin S, Bewshea C, et al. Mechanisms and management of loss of response to anti-tnf therapy for patients with crohn's disease: 3-year data from the prospective, multicentre pants cohort study. *Lancet Gastroenterol Hepatol*. 2024;9(6):521-538
14. Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. *Am J Gastroenterol*. 2021;116(10):2014-2025.
15. Devlin, SM, Dubinsky, MC. Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. *Inflamm Bowel Dis* 2008; 14:125.
16. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. *Inflamm Bowel Dis*. 2007; 13(9):1100-1105.
17. D'Haens G, Vermeire S, Lambrecht G, et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn's disease. *Gastroenterology*. 2018;154(5):1343-1351.e1341
18. D'Incà R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? *Am J Gastroenterol*. 2008; 103(8):2007-2014.
19. Dotan, I. Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. *Expert Rev Gastroenterol Hepatol* 2007; 1:265.
20. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease

- treated with azathioprine or 6-mercaptopurine. *Am J Gastroenterol.* 2005; 100:1-9.
21. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: A metaanalysis. *Am J Gastroenterol.* 2004;99(12):2393-2404
 22. Fernandes SR, Bernardo S, Simões C, Gonçalves AR, Valente A, Baldaia C, Santos, PM, Correia LA, Marinho RT. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease. *Inflamm Bowel Dis.* 2020;26(2):263-270.
 23. Ferrante, M, Henckaerts, L, Joossens, M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. *Gut* 2007; 56:1394.
 24. Feuerstein JD et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. *Gastroenterology.* 2017; 153 (3): 827-834.
 25. Ford AC, Chey WD, Talley NJ, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome. *Arch Intern Med.* 2009; 169(7):651-658.
 26. Gemelli Biotech. [Triosmart](#) (Accessed January 27, 2025).
 27. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. *Dig Liver Dis.* 2009; 41(1):56-66.
 28. Hadithi M, von Blomberg BM, Crusius JB, et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. *Ann Intern Med.* 2007; 147(5):294-302.
 29. Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr.* 2005; 40(1):1-19.
 30. Hoerter NA, Shannahan SE, Suarez J, et al. Diagnostic yield of isolated deamidated gliadin peptide antibody elevation for celiac disease. *Dig Dis Sci* 2017;62(5):1272–6.
 31. Holland K, Bennett WE, Slaven JE, Collier J, Waltz G, Pfefferkorn M. Proactive measurement of infliximab drug levels in children with Crohn's disease. *Ann Gastroenterol.* 2022;35(1):56-62.
 32. Hyams, J. et al. Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children, *Gastroenterology* 2012; 143:365–374.
 33. Kamperidis N, Middleton P, Tyrrell T, Stasinou I, Arebi N. Impact of therapeutic drug level monitoring on outcomes of patients with Crohn's disease treated with infliximab: real world data from a retrospective single centre cohort study. *Frontline Gastroenterol.* 2019;10(4):330-336.
 34. Kaukinen K, Partanen J, Maki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. *Am J Gastroenterol.* 2002; 97(3):695-699.
 35. Kelly, Ciarán. Diagnosis of celiac disease in adults. In: *UpToDate*, Connor RF (Ed), Wolters Kluwer. Last updated Feb 14, 2023 (Accessed on April 4, 2024)

36. Kim ES, Kwon Y, Choe YH, Kim MJ. Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric crohn's disease patients with secondary loss of response. *Therap Adv Gastroenterol.* 2023;16:17562848231170948.
37. Leffler DA, Kelly CP. Update on the evaluation and diagnosis of celiac disease. *Curr Opin Allergy Clin Immunol.* 2006; 6(3):191-196.
38. Lewis NR, Scott BB. Meta-analysis: Deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. *Aliment Pharmacol Ther.* 2010; 31(1):73-81.
39. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute Medical Position Statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. *Gastroenterol.* 2006; 130:935-939.
40. Lichtenstein GR, Hanauer SB, Sandborn WJ, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. *Am J Gastroenterol.* 2009; 104(2):465-483.
41. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2018 Apr;113(4):481-517. doi: 10.1038/ajg.2018.27. Epub 2018 Mar 27. Erratum in: *Am J Gastroenterol.* 2018 Jul;113(7):1101. PMID: 29610508.
42. Liu E, Rewers M, Eisenbarth GS. Genetic testing: Who should do the testing and what is the role of genetic testing in the setting of celiac disease? *Gastroenterology.* 2005; 128(4 Suppl 1):S33-S37.
43. Marton A, Xue X, Szilagyi A. Meta-analysis: the diagnostic accuracy of lactose breath hydrogen or lactose tolerance tests for predicting the North European lactase polymorphism C/T-13910. *Aliment Pharmacol Ther.* 2012 Feb;35(4):429-40. doi: 10.1111/j.1365-2036.2011.04962.x. Epub 2011 Dec 28. PMID: 22211845.
44. Mokrowiecka A, Daniel P, Słomka M, et al. Clinical utility of serological markers in inflammatory bowel disease. *Hepatogastroenterology.* 2009; 56(89):162-166.
45. Mow, WS, Vasiliasuskas, EA, Lin, YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. *Gastroenterology* 2004; 126:414.
46. McGowan KE, Lyon ME, Butzner JD. Celiac disease and IgA deficiency: Complications of serological testing approaches encountered in the clinic. *Clin Chem.* 2008; 54(7):1203-1209.
47. Megiorni F, Mora B, Bonamico M, et al. A rapid and sensitive method to detect specific human lymphocyte antigen (HLA) class II alleles associated with celiac disease. *Clin Chem Lab Med.* 2008; 46(2):193-196.
48. Murphy, SJ, Kornbluth, A. Serologic and genetic markers do not aid in the determination of the clinical course and severity of patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2008; 14:129.

49. Nandiwada SL, Tebo AE. Testing for antireticulin antibodies in patients with celiac disease is obsolete: a review of recommendations for serologic screening and the literature. *Clin Vaccine Immunol.* 2013 Apr;20(4):447-51.
50. National Institute for Diabetes and Digestive and Kidney Disease. Ulcerative Colitis. Available at <https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis> (Accessed December 31, 2024).
51. Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, Cheifetz AS. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. *Clin Gastroenterol Hepatol.* 2017;15(10):1580-1588.e1583.
52. Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol.* 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27. PMID: 30928454; PMCID: PMC6661210.
53. Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. *World J Gastroenterol.* 2006; 12(23):3657-3667.
54. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. *Am J Gastroenterol.* 2020 Feb;115(2):165-178. doi: 10.14309/ajg.0000000000000501. PMID: 32023228.
55. Prause C, Ritter M, Probst C, et al. Antibodies against deamidated gliadin as new and accurate biomarkers of childhood coeliac disease. *J Pediatr Gastroenterol Nutr.* 2009; 49(1):52-58.
56. Rashtak S, Murray JA. Tailored testing for celiac disease. *Ann Intern Med.* 2007; 147(5):339-341.
57. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. *Am J Gastroenterol.* 2017 May;112(5):775-784. doi: 10.1038/ajg.2017.46. Epub 2017 Mar 21. PMID: 28323273; PMCID: PMC5418558.
58. Ricciuto A, Dhaliwal J, Walters TD, Griffiths AM, Church PC. Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis. *J Crohns Colitis.* 2018;12(11):1302-1315.
59. Rubin DT, Ananthkrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol.* 2019 Mar;114(3):384-413. PMID: 30840605.
60. Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Greer KB, Limketkai BN, Lebwohl B. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. *Am J Gastroenterol.* 2023 Jan 1;118(1):59-76. doi: 10.14309/ajg.0000000000002075. Epub 2022 Sep 21. PMID: 36602836.
61. Setty M, Hormaza L, Guandalini S. Celiac disease: Risk assessment, diagnosis, and monitoring. *Mol Diagn Ther.* 2008; 12(5):289-298.

62. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: Clinical pharmacology and implication of pharmacogenetically guided dosing. *Clin Pharmacokinet.* 2007; 46(3):187-208.
63. US Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, Ebell M, Epling JW Jr, Herzstein J, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Screening for Celiac Disease: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2017 Mar 28;317(12):1252-1257. doi: 10.1001/jama.2017.1462. PMID: 28350936.
64. Vécsei AK, Graf UB, Vogelsang H. Follow-up of adult celiac patients: Which noninvasive test reflects mucosal status most reliably? *Endoscopy.* 2009; 41(2):123-128.
65. van der Windt DA, Jellema P, Mulder CJ, et al. Diagnostic testing for celiac disease among patients with abdominal symptoms: A systematic review. *JAMA.* 2010; 303(17):1738-1746.
66. von Stein P, Lofberg R, Kuznetsov NV, et al. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. *Gastroenterology.* 2008;134(7):1869-2154.
67. Villalta D, Tonutti E, Prause C, et al. IgG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IgA deficiency. *Clin Chem.* 2010; 56(3):464-468.
68. Waljee AK, Joyce JC, Wang S, et al. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. *Clin Gastroenterol Hepatol.* 2010;8(2):143-150

AMA CPT Copyright Statement:

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.